https://www.selleckchem.com/products/gm6001.html
An all-case, single-arm, observational, postmarketing surveillance is underway to assess the safety of tafamidis in patients with hereditary transthyretin (ATTRv) amyloidosis with peripheral polyneuropathy, also called transthyretin-type familial amyloid polyneuropathy, in Japan. Results from an interim analysis (data cutoff date, May 15, 2018) are presented in this preliminary report. Patients were registered and treated with tafamidis meglumine 20mg/d in routine clinical practice (observation period, 156 weeks). Data on patient demogra
Like
Comment
Share
